S&P 500 7,746 +0.29% Nasdaq 26,596 +0.88% Dow Jones 53,817 -0.98% FTSE 100 10,832 -0.52% DAX 26,414 +1.10% Nikkei 225 67,524 +1.85% Hang Seng 25,440 -1.84% WTI Crude 82.71 +5.79% Gold 4,496 +3.58% US 10-Year Treasury Yield 4.668 -0.04% S&P 500 7,746 +0.29% Nasdaq 26,596 +0.88% Dow Jones 53,817 -0.98% FTSE 100 10,832 -0.52% DAX 26,414 +1.10% Nikkei 225 67,524 +1.85% Hang Seng 25,440 -1.84% WTI Crude 82.71 +5.79% Gold 4,496 +3.58% US 10-Year Treasury Yield 4.668 -0.04%

LATEST

Big 6 audit firms earn N175 billion, PwC leads clients, KPMG revenue●Nvidia, Apple, Google fuel record $185 billion gain for Norway’s wealth fund, but CEO say, ‘We are really cautious’●Lumentum’s stock surges, giving a further boost to the optical-networking trade●Coinbase, Polymarket, Kalshi Face NYC Prediction Market Investigation●Social Security COLA estimates for 2027 fall as inflation moderates●Pilani Investment to sell 1.7 million UltraTech Cement shares for ₹1,908 crore●A Routing Bug Took Solana 86% of the Way to Losing Finality●Scott Bessent's Hormuz declaration puts Chevron at the center●Big 6 audit firms earn N175 billion, PwC leads clients, KPMG revenue●Nvidia, Apple, Google fuel record $185 billion gain for Norway’s wealth fund, but CEO say, ‘We are really cautious’●Lumentum’s stock surges, giving a further boost to the optical-networking trade●Coinbase, Polymarket, Kalshi Face NYC Prediction Market Investigation●Social Security COLA estimates for 2027 fall as inflation moderates●Pilani Investment to sell 1.7 million UltraTech Cement shares for ₹1,908 crore●A Routing Bug Took Solana 86% of the Way to Losing Finality●Scott Bessent's Hormuz declaration puts Chevron at the center●

Wealth

Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide

MarketWatch.com - Top Stories · 1h ago · 🇺🇸 United States

Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide

Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.

Read the full story at MarketWatch.com - Top Stories →

More Wealth

Lumentum’s stock surges, giving a further boost to the optical-networking trade

MarketWatch.com - Top Stories · 15m ago

Social Security COLA estimates for 2027 fall as inflation moderates

Personal Finance · 20m ago

Nebius adds to the excitement around neocloud stocks with upbeat earnings of its own

MarketWatch.com - Top Stories · 1h ago

The $30 trillion Treasury market is facing a painful reckoning. How rising yields could squeeze your portfolio.

MarketWatch.com - Top Stories · 1h ago